These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 25253844

  • 1. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
    Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M.
    J Neurosci; 2014 Sep 24; 34(39):12953-62. PubMed ID: 25253844
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
    Mabrouk OS, Marti M, Morari M.
    Neuroscience; 2010 Mar 10; 166(1):40-8. PubMed ID: 20006677
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
    Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.
    Neurobiol Dis; 2016 May 10; 89():55-64. PubMed ID: 26804029
    [Abstract] [Full Text] [Related]

  • 7. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
    Marti M, Trapella C, Morari M.
    J Neurochem; 2008 Dec 10; 107(6):1683-96. PubMed ID: 19014386
    [Abstract] [Full Text] [Related]

  • 8. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
    Volta M, Viaro R, Trapella C, Marti M, Morari M.
    Exp Neurol; 2011 Mar 10; 228(1):126-37. PubMed ID: 21215744
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.
    Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M.
    Neurobiol Dis; 2008 Jun 10; 30(3):430-438. PubMed ID: 18413287
    [Abstract] [Full Text] [Related]

  • 13. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
    Volta M, Mabrouk OS, Bido S, Marti M, Morari M.
    J Neurochem; 2010 Dec 10; 115(6):1543-55. PubMed ID: 20950413
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
    Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, Tozzi A, Brambilla R, Calabresi P, Simonato M, Bezard E, Morari M.
    J Neurosci; 2012 Nov 14; 32(46):16106-19. PubMed ID: 23152595
    [Abstract] [Full Text] [Related]

  • 16. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
    Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L.
    J Pharmacol Exp Ther; 2009 Dec 14; 331(3):946-53. PubMed ID: 19713488
    [Abstract] [Full Text] [Related]

  • 17. Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures.
    Bregola G, Zucchini S, Rodi D, Binaschi A, D'Addario C, Landuzzi D, Reinscheid R, Candeletti S, Romualdi P, Simonato M.
    J Neurosci; 2002 Nov 15; 22(22):10030-8. PubMed ID: 12427860
    [Abstract] [Full Text] [Related]

  • 18. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
    Rutten K, Tzschentke TM, Koch T, Schiene K, Christoph T.
    Eur J Pharmacol; 2014 Oct 15; 741():264-71. PubMed ID: 25169429
    [Abstract] [Full Text] [Related]

  • 19. NOP Receptor Ligands and Parkinson's Disease.
    Mercatelli D, Pisanò CA, Novello S, Morari M.
    Handb Exp Pharmacol; 2019 Oct 15; 254():213-232. PubMed ID: 30689087
    [Abstract] [Full Text] [Related]

  • 20. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
    Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candeletti S, Simonato M, Cox BM, Morari M.
    J Neurosci; 2005 Oct 19; 25(42):9591-601. PubMed ID: 16237164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.